Skip to content
DataLookout
Menu

NCT02573766

Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved 2 years later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 21 versions: 14 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Oct 1, 2026 to Oct 1, 2028
    • Eligibility criteria expanded, about 15 words
    • Study description expanded, about 9 words
  2. Study Identification, Study Status, Oversight, IPDSharingv19
  3. Notable Primary and study completion dates: Oct 1, 2024 to Oct 1, 2026v18
  4. Notable Primary and study completion dates pushed to Oct 1, 2024v13
  5. Minor Study completion date: Oct 2019 to Oct 2020v12
Show 8 earlier versionsHide 8 earlier versions
  1. Minor Study completion date: Oct 2020 to Oct 2019v11
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 99 to confirmed 91
    • Start date: Oct 2015 to Oct 1, 2015
    • Site details revised
    v10
  3. Minor Enrollment target: 100 to 99v9
  4. Minor Enrollment target: 90 to 100
    • Study description shortened, about 66 words
    v8
  5. Minor Study completion date: Oct 2019 to Oct 2020v7
  6. Notable Eligibility criteria shortened, about 28 words
    • Study completion date: Oct 2019
    • Study description revised
    v6
  7. Minor Collaborators: 1 to 2v3
  8. Minor Study description expanded, about 62 wordsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Effects of Active, Deactivated, and No Neurofeedback (NF) on Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Timeframe: 4 months

Secondary (1)

Effects of Neurofeedback on the Cortical and Subcortical Regions of the Pain Matrix Associated with Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Arms and interventions

Neurofeedback TrainingExperimental

Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.

Sham Neurofeedback TrainingSham comparator

Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.

Standard of CareOther

Seven questionnaires regarding symptoms and quality of life completed at baseline, at follow up, and again in one month. Participants receive EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.

Procedures: Neurofeedback Training, Electroencephalogram

Behavioral: Pain Scale, Questionnaires

Sites

1 site in 1 country

  • University of Texas MD Anderson Cancer CenterHouston, Texas, United States